Cargando…

Monitoring the effect of belinostat in solid tumors by H4 acetylation

Histone deacetylase (HDAC) inhibition is a novel entity in medical oncology, and several HDAC inhibitors are in clinical trials. One of them is the hydroxamic acid belinostat (PXD101) that has demonstrated therapeutic efficacy for several clinical indications. Acetylation of histones is a key event...

Descripción completa

Detalles Bibliográficos
Autores principales:	MARQUARD, LENA, PETERSEN, KAMILLE DUMONG, PERSSON, MORTEN, HOFF, KIRSTEN DAMGAARD, JENSEN, PETER BUHL, SEHESTED, MAXWELL
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2008
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2774150/ https://www.ncbi.nlm.nih.gov/pubmed/18452428 http://dx.doi.org/10.1111/j.1600-0463.2008.00957.x

Ejemplares similares

[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice
por: Jensen, Mette Munk, et al.
Publicado: (2013)

Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells
por: Dejligbjerg, Marielle, et al.
Publicado: (2008)

Early Detection of Response to Experimental Chemotherapeutic Top216 with [(18)F]FLT and [(18)F]FDG PET in Human Ovary Cancer Xenografts in Mice
por: Munk Jensen, Mette, et al.
Publicado: (2010)

Imaging of Treatment Response to the Combination of Carboplatin and Paclitaxel in Human Ovarian Cancer Xenograft Tumors in Mice Using FDG and FLT PET
por: Munk Jensen, Mette, et al.
Publicado: (2013)

[18F]FLT PET for Non-Invasive Assessment of Tumor Sensitivity to Chemotherapy: Studies with Experimental Chemotherapy TP202377 in Human Cancer Xenografts in Mice
por: Munk Jensen, Mette, et al.
Publicado: (2012)

[18F]FLT and [18F]FDG PET for Non-invasive Treatment Monitoring of the Nicotinamide Phosphoribosyltransferase Inhibitor APO866 in Human Xenografts
por: Munk Jensen, Mette, et al.
Publicado: (2013)

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours
por: Lassen, U, et al.
Publicado: (2010)

Ritonavir Interacts With Belinostat to Cause Endoplasmic Reticulum Stress and Histone Acetylation in Renal Cancer Cells
por: Isono, Makoto, et al.
Publicado: (2016)

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma
por: Marquard, L, et al.
Publicado: (2008)

Repurposing Belinostat for Alleviation of Atopic Dermatitis
por: Quah, Shan, et al.
Publicado: (2021)

Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
por: Hood, Katelyn, et al.
Publicado: (2016)

Hematologic toxicity is rare in relapsed patients treated with belinostat: a systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas
por: Allen, Pamela B, et al.
Publicado: (2018)

Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
por: Bodiford, Andrew, et al.
Publicado: (2014)

Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer
por: Chan, Daniel, et al.
Publicado: (2013)

New developments in the treatment of peripheral T-cell lymphoma – role of Belinostat
por: Reimer, Peter
Publicado: (2015)

Preclinical efficacy of belinostat in combination with zidovudine in adult T-cell leukemia-lymphoma
por: Toomey, Ngoc, et al.
Publicado: (2015)

Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma
por: Reimer, Peter, et al.
Publicado: (2013)

Belinostat exerts antitumor cytotoxicity through the ubiquitin‐proteasome pathway in lung squamous cell carcinoma
por: Kong, Li R., et al.
Publicado: (2017)

Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat
por: Chang, Chi-Ming, et al.
Publicado: (2023)

The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
por: Buckley, Michael T, et al.
Publicado: (2007)

Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients
por: Wang, Ling-Zhi, et al.
Publicado: (2013)

A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction
por: Takebe, Naoko, et al.
Publicado: (2019)

Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells
por: Jensen, Lars H, et al.
Publicado: (2004)

Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer
por: Dovzhanskiy, Dmitriy I, et al.
Publicado: (2012)

Correction: Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients
por: Wang, Ling-Zhi, et al.
Publicado: (2014)

Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors
por: Lobo, João, et al.
Publicado: (2020)

Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling
por: Valiuliene, Giedre, et al.
Publicado: (2015)

A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas
por: Vitfell-Rasmussen, Joanna, et al.
Publicado: (2016)

Metabolism and Pharmacokinetic Study of the Boron-Containing Prodrug of Belinostat (ZL277), a Pan HDAC Inhibitor with Enhanced Bioavailability
por: Zhang, Changde, et al.
Publicado: (2019)

Anti-multiple myeloma potential of resynthesized belinostat derivatives: an experimental study on cytotoxic activity, drug combination, and docking studies
por: Nguyen, Hong Phuong, et al.
Publicado: (2022)

Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor – belinostat – in glioblastoma cell lines: a preliminary report
por: Kusaczuk, Magdalena, et al.
Publicado: (2016)

17-AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA-MB-231 breast cancer cells
por: Zuo, Yu, et al.
Publicado: (2020)

Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma
por: Johnston, Patrick B., et al.
Publicado: (2021)

Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model
por: Kaczmarek, Jessica V., et al.
Publicado: (2021)

Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro
por: Peters, Godefridus J., et al.
Publicado: (2020)

CXCL1 Clone Evolution Induced by the HDAC Inhibitor Belinostat Might Be a Favorable Prognostic Indicator in Triple-Negative Breast Cancer
por: Han, Xin-le, et al.
Publicado: (2021)

Prolonging the Half-Life of Histone Deacetylase Inhibitor Belinostat via 50 nm Scale Liposomal Subcutaneous Delivery System for Peripheral T-Cell Lymphoma
por: Cheng, Meng-Hsuan, et al.
Publicado: (2020)

Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma
por: Xu, Karen, et al.
Publicado: (2022)

Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T‐cell lymphoma: A case report
por: Camus, Vincent, et al.
Publicado: (2023)

Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1
por: Wang, Lingzhi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_brhkvt972migi9633uidsn4n26